Zubin Bhagwagar, MBBS, MD, FRCPsych, DPhil
DownloadHi-Res Photo
About
Biography
Zubin is a physician scientist with 30 years of experience in academia and the pharmaceutical industry and is the Chief Medical Officer at Certego Therapeutics. Previously, Zubin was SVP R&D at Rallybio (a rare disease focussed biotech which went public in 2021) and Vice President and Head of External Innovation at Alexion Pharmaceuticals, where he also led the Strategic Evaluation team in Business Development. He previously held positions of increasing responsibility at Bristol-Myers Squibb, where he worked in multiple therapeutic areas including neuroscience and clinical pharmacology and was in academia prior to BMS.
Zubin received his medical degree and completed his psychiatry residency at Delhi University. He subsequently completed another residency in psychiatry at the University of Oxford, where he was awarded a DPhil (Ph.D.) in neuroimaging and neurobiology. He is a Fellow of the Royal College of Psychiatrists (UK) and the American College of Neuropsychopharmacology, has authored more than 80 papers in neuroscience/psychiatry, and has been on the faculty of the Department of Psychiatry at Yale University School of Medicine since 2005, where he is an Adjunct Associate Professor.
Appointments
Departments & Organizations
Education & Training
- DPhil
- University of Oxford (2004)
- Medical Research Council Clinical Training Fellow
- Medical School, University Of Oxford (2001)
- Clinical Research Fellow
- Institute of Psychiatry, King's College London (1999)
- Resident
- University of Oxford (1998)
- MD
- Maulana Azad Medical College (1994)
- Resident
- University of Delhi (1994)
- MBBS
- Maulana Azad Medical College (1989)
Board Certifications
Psychiatry
- Certification Organization
- The Royal College of Psychiatrists
- Original Certification Date
- 1998
Research
Overview
Medical Research Interests
Affective Disorders, Psychotic; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neurobiology; Neuroimaging; Neuropsychiatry; Neurosciences; Psychiatry; Psychopharmacology
ORCID
0000-0002-1101-768X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Zubin Bhagwagar's published research.
Publications Timeline
A big-picture view of Zubin Bhagwagar's research output by year.
Research Interests
Research topics Zubin Bhagwagar is interested in exploring.
Gilles Tamagnan, PhD
Irina Esterlis, PhD
John Krystal, MD
Deepak Cyril Dsouza, MBBS, MD
Godfrey Pearlson, MA, MBBS
Hilary Blumberg, MD
68Publications
2,767Citations
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging
Publications
2022
An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study
Geisen C, Kjaer M, Fleck E, Skogen B, Armstrong R, Behrens F, Bhagwagar Z, Braeuninger S, Mortberg A, Olsen K, Gastón Schäfer S, Walter C, Seifried E, Wikman A, Kjeldsen-Kragh J, Koehm M. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study. Journal Of Thrombosis And Haemostasis 2022, 21: 838-849. PMID: 36696185, DOI: 10.1016/j.jtha.2022.11.041.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFetal/Neonatal Alloimmune ThrombocytopeniaNeonatal alloimmune thrombocytopeniaHPA-1aAlloimmune thrombocytopeniaHuman platelet antigen 1aTreatment-emergent adverse eventsPlacebo 1 hourHPA-1a antibodiesFNAIT casesHyperimmune IgGPrimary endpointAdverse eventsFetus/Healthy menSingle doseAntigen 1aHLA-A2Concept studyCohort 1PlaceboFlow cytometryThrombocytopeniaPlateletsAdministrationWeeks
2019
Lithium for acute mania
Bhagwagar Z, Goodwin G, Geddes J. Lithium for acute mania. 2019, 2019 PMCID: PMC6524414, DOI: 10.1002/14651858.cd004048.pub3.Peer-Reviewed Original Research
2012
P2‐412: A comparison of hippocampal atrophy algorithms to select outcome measures for clinical trials in mild‐to‐moderate Alzheimer's disease
Burns L, Rueckert D, Bhagwagar Z, Donohue M, Wolz R, Tiller J, Soares H, l'Italien G, Coric V, Hayes W, Fox N, Berman R. P2‐412: A comparison of hippocampal atrophy algorithms to select outcome measures for clinical trials in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2012, 8: p408-p408. DOI: 10.1016/j.jalz.2012.05.2037.Peer-Reviewed Original ResearchP2‐423: vMRI and whole‐brain volume in patients with mild‐to‐moderate Alzheimer's disease
Budd D, Nalysnyk L, Fahrbach K, Bhagwagar Z, Berman R, Burns L, l'Italien G. P2‐423: vMRI and whole‐brain volume in patients with mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2012, 8: p411-p412. DOI: 10.1016/j.jalz.2012.05.2048.Peer-Reviewed Original ResearchP2‐422: vMRI and hippocampal volume in patients with suspected predementia Alzheimer's disease
Budd D, Nalysnyk L, Fahrbach K, Bhagwagar Z, Berman R, Burns L, l'Italien G. P2‐422: vMRI and hippocampal volume in patients with suspected predementia Alzheimer's disease. Alzheimer's & Dementia 2012, 8: p411-p411. DOI: 10.1016/j.jalz.2012.05.2047.Peer-Reviewed Original ResearchAntidepressants
Bhagwagar Z, Heninger G. Antidepressants. 2012, 1185-1198. DOI: 10.1093/med/9780199696758.003.0153.Peer-Reviewed Original ResearchConceptsWorld Health Organization Global BurdenMajor public health problemPharmacology of antidepressantsLargest causeTreatment of depressionMajor depressive disorderPublic health problemAbstract Major depressive disorderImportance of depressionRecurrent illnessDepressive disorderPrimary treatmentAntidepressant drugsGlobal burdenHigh riskHealth problemsDepressionAntidepressantsDrugsPatientsDepressed individualsSelective useCliniciansBurdenDisease
2011
Abnormal prefrontal activity subserving attentional control of emotion in remitted depressed patients during a working memory task with emotional distracters
Kerestes R, Ladouceur CD, Meda S, Nathan PJ, Blumberg HP, Maloney K, Ruf B, Saricicek A, Pearlson GD, Bhagwagar Z, Phillips ML. Abnormal prefrontal activity subserving attentional control of emotion in remitted depressed patients during a working memory task with emotional distracters. Psychological Medicine 2011, 42: 29-40. PMID: 21733287, DOI: 10.1017/s0033291711001097.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVentrolateral prefrontal cortexNegative emotional informationFunctional magnetic resonance imagingEmotional distractersAttentional controlEmotional informationMemory taskMemory loadEmotional Face N-Back (EFNBACK) taskOrbitofrontal cortexNegative emotional distractersN-back taskInterface of cognitionAccurate task performanceKey neural circuitsBlood oxygen level-dependent functional magnetic resonance imagingRMDD patientsLevel-dependent functional magnetic resonance imagingAttentional biasesFacial emotionsEmotion processingDepressed patientsDistracter stimuliTrait-like abnormalitiesRight DLPFC
2010
Increased peripheral blood expression of electron transport chain genes in bipolar depression
Beech RD, Lowthert L, Leffert JJ, Mason PN, Taylor MM, Umlauf S, Lin A, Lee JY, Maloney K, Muralidharan A, Lorberg B, Zhao H, Newton SS, Mane S, Epperson CN, Sinha R, Blumberg H, Bhagwagar Z. Increased peripheral blood expression of electron transport chain genes in bipolar depression. Bipolar Disorders 2010, 12: 813-824. PMID: 21176028, PMCID: PMC3076072, DOI: 10.1111/j.1399-5618.2010.00882.x.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBipolar disorderBipolar depressionPeripheral bloodDepressed subjectsGeneGo MetaCore softwarePeripheral blood expressionHealthy control subjectsReal-time reverse transcription-polymerase chain reactionEffects of medicationReverse transcription-polymerase chain reactionQuantitative real-time reverse transcription-polymerase chain reactionTranscription-polymerase chain reactionMitochondrial electron transport chainControl subjectsPolymerase chain reactionUnmedicated subjectsHealthy controlsBlood expressionBPD subjectsSpecific genetic pathwaysElectron transport chain genesMetaCore softwareA totalAltered expressionQRT-PCRLevetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2010, 72: 744-50. PMID: 21034692, DOI: 10.4088/jcp.09m05659gre.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDepression Rating ScaleRating ScaleMean changeWeek 6Clinical Global Impression-Bipolar Version ScaleBipolar disorderHamilton Depression Rating Scale scoresMontgomery-Åsberg Depression Rating ScalePlacebo-controlled clinical trialDepression Rating Scale scoresHamilton Depression Rating ScaleYoung Mania Rating ScaleAdjunctive levetiracetam therapyLevetiracetam adjunctive therapySecondary efficacy assessmentsBipolar disorder type IPlacebo-controlled trialHamilton Anxiety Rating ScalePrimary efficacy measureSecondary outcome measuresMajor depressive episodeRating Scale scoresMania Rating ScaleShort-term treatmentSignificant differencesThe Relationship Between Mood, Stress, and Tobacco Smoking
Walderhaug E, Cosgrove K, Bhagwagar Z, Neumeister A. The Relationship Between Mood, Stress, and Tobacco Smoking. 2010, 147-161. DOI: 10.1007/978-1-4419-6373-4_10.Peer-Reviewed Original ResearchConceptsTobacco smokingPrimary addictive substancePositron emission tomographySingle photon emissionNicotine sharesTobacco smokeNicotine dependenceNicotine addictionHealthy peopleAbuse potentialEmission tomographyBehavioral effectsAnxiety disordersAddictive substancesSmokingHigh rateNicotineMolecular imagingMoodTomographyPsychostimulantsIndividuals